Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by TommyNickelson Oct 27, 2024 8:11am
120 Views
Post# 36283838

RE:RE:RE:Seriously? 3:1

RE:RE:RE:Seriously? 3:1A reverse split with a clear path to uplist to a senior exchange is not a bad idea.

If Roger can raise several million at 30 cents then  well done. If he's raising another 500K that's another story.

He would be better off raising more money for a lower price than less money at a higher one. The longer he drags out getting patients treated, the longer to market. 

The great thing is that we will know soon. 

His stated goal is to complete 100 patients by end of 2024. One, this costs money. Two, operating timeslots need to be available. These clinics aren't going to book / screen patients if they aren't paid.

My guess (just a guess) is that we are still at 75 patients. This is why they've opened the door to Q1. And why Roger hinted 85 patients might be good. I suspect they are asking thr FDA if stopping at say, 78, is acceptable. It's about money.

I hope to be able to buy back in. Theralase is a compelling story. But yes, it's not a perfect story. 
<< Previous
Bullboard Posts
Next >>